OSRH

OSR Health Inc

0.4302

Jul 23 • 12:18 PM ET -0.0088 (-2.00%)

Healthcare Biotechnology USA Nano NASD

Peers: CMMB COCP CVKD HCWB HIND INAB LEXX MTVA NCEL XCUR

Index	-
Market Cap	15.11M
Enterprise Value	42.02M
Income	-9.55M
Sales	2.63M
Book/sh	3.12
Cash/sh	0.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Mar 17, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	5.75
P/B	0.14
P/C	9.62
P/FCF	-
EV/EBITDA	-
EV/Sales	15.98
Quick Ratio	0.14
Current Ratio	0.16
Debt/Eq	0.05
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.36
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-518.53% -214.49%
Sales past 3/5Y	- -
EPS Y/Y TTM	82.05%
Sales Y/Y TTM	245.29%
EPS Q/Q	91.01%
Sales Q/Q	-36.41%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	44.72%
Insider Trans	0.00%
Inst Own	0.83%
Inst Trans	6.65%
ROA	-5.51%
ROE	-10.63%
ROIC	-9.17%
Gross Margin	-337.60%
Oper. Margin	-726.07%
Profit Margin	-363.30%
SMA20	16.47%
SMA50	2.82%
SMA200	-20.33%
Trades

Shs Outstand	33.30M
Shs Float	19.41M
Short Float	7.30%
Short Ratio	0.22
Short Interest	1.42M
52W High	1.24 -65.31%
52W Low	0.30 43.35%
Volatility	12.68% 10.26%
ATR (14)	0.04
RSI (14)	56.44
Beta	0.59
Rel Volume	0.05
Avg Volume	6.43M
Volume	147,181

Perf Week	-11.41%
Perf Month	19.17%
Perf Quarter	-26.56%
Perf Half Y	-38.10%
Perf YTD	-23.74%
Perf Year	-57.82%
Perf 3Y	-95.82%
Perf 5Y	-
Perf 10Y	-
Recom	2.00
Target Price	10.00
Prev Close	0.44
Price	0.43
Change	-2.00%

Jul-13-26 12:37PM	OSR Health, A Message From the CEO (ACCESSWIRE) +8.40%
Jul-02-26 01:05PM	CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target (ACCESSWIRE)
09:00AM	Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target (ACCESSWIRE)
Jun-25-26 08:32AM	OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares (ACCESSWIRE)
Jun-22-26 09:06AM	OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do (ACCESSWIRE) -5.77%
12:05PM	Loading…
Jun-03-26 12:05PM	CEO Statement to Shareholders (ACCESSWIRE)
May-27-26 09:06AM	OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction (ACCESSWIRE)
May-12-26 09:16AM	CEO Statement to Shareholders (ACCESSWIRE) +13.09%
May-05-26 01:05PM	Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target (ACCESSWIRE) -10.76%
Apr-30-26 10:30AM	BC-Most Active Stocks (Associated Press) +52.80%
09:15AM	OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 (ACCESSWIRE)
Apr-29-26 09:50AM	OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe (ACCESSWIRE) -38.19%
Apr-09-26 09:15AM	OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note (ACCESSWIRE)
Mar-30-26 09:00AM	OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026 (ACCESSWIRE) +13.84%
Mar-27-26 09:00AM	Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target (ACCESSWIRE) +5.57%
08:30AM	Loading…
Mar-23-26 08:30AM	OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level (ACCESSWIRE) +9.59%
Mar-19-26 09:44AM	Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials (PR Newswire)
08:55AM	Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities (ACCESSWIRE)
Mar-05-26 09:30AM	OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum (ACCESSWIRE) +14.67%
Feb-02-26 09:50AM	CEO Statement to Shareholders (ACCESSWIRE)
Jan-27-26 08:30AM	OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries (ACCESSWIRE)
Jan-22-26 09:55AM	Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch (PR Newswire) +10.23%
Jan-16-26 09:20AM	Vaximm Appoints Sebastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform (PR Newswire)
Jan-12-26 08:05AM	Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones (PR Newswire) +8.26%
Dec-19-25 11:50AM	Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings (PR Newswire) +13.65%
Dec-04-25 03:19PM	Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement (Newsfile) +9.99%
Dec-02-25 09:53AM	Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months (PR Newswire)
Dec-01-25 03:01PM	OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 (PR Newswire)
Nov-21-25 09:20AM	Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones (PR Newswire) +23.38%
Nov-14-25 11:10AM	OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion (PR Newswire) -8.83%
08:30AM	Loading…
Nov-06-25 08:30AM	OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study (PR Newswire) +13.98%
Oct-20-25 11:40AM	Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target (Newsfile) +25.67%
Oct-14-25 08:30AM	OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care (PR Newswire)
Sep-09-25 05:30PM	OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity (PR Newswire) +9.58%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +96.12%
Aug-01-25 01:29PM	OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025 (PR Newswire) -6.67%
Jul-31-25 12:45PM	OSR Holdings Provides Transparency Update on Equity Financing Instruments (PR Newswire) -20.44%
Jul-30-25 04:10PM	OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure (PR Newswire) -6.99%
Jul-28-25 05:49AM	OSR Holdings to acquire South Koreas medical device company Woori IO (Medical Device Network)
Jul-24-25 07:30AM	OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology (PR Newswire) -5.88%
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire) -7.02%
Jul-08-25 10:03AM	OSR Holdings Announces Strategic Roadmap for Tokenization Under Reg D Framework in Partnership with BCM Europe AG (PR Newswire)
May-22-25 07:36AM	OSR Holdings, BCM Europe, and Taekwondo Cooperative Announce Strategic MOU to Launch Blockchain-Based OSRH Token (PR Newswire) +5.25%
May-02-25 07:30AM	Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics (PR Newswire)
Apr-09-25 07:54AM	Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology (PR Newswire)
Apr-03-25 07:30AM	OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies (PR Newswire) +68.03%
Mar-26-25 07:16AM	Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma (PR Newswire) +136.87%
Mar-25-25 07:00AM	OSR Holdings Appoints Dr. Constance Hfer as Chief Scientific Officer (PR Newswire) -7.51%

OSR Health, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

Chairman & CEOMr. Kuk Hyoun Hwang

Chief Financial OfficerMr. Gihyoun Bang

Chief Scientific OfficerDr. Constance Hofer

Chief Legal OfficerMr. Jun Chul Whang

Chief Operating OfficerMr. Yeiseok Kim

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OSRH

OSR Health Inc

Upgrade your Finviz experience